Genital Herpes – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Genital
Herpes – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Genital Herpes – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Genital Herpes (Infectious Disease), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of
key players involved in therapeutic development for Genital Herpes and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies/Universities/Institutes, the
molecules developed by Companies in Phase II, Phase I, Preclinical and
Discovery stages are 3, 5, 18 and 2 respectively. Similarly, the
Universities portfolio in Preclinical stages comprises 1 molecules,
respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Genital Herpes (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Genital Herpes
  (Infectious Disease) by companies and universities/research institutes
  based on information derived from company and industry-specific
  sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Genital Herpes
  (Infectious Disease) therapeutics and enlists all their major and
  minor projects.
• The pipeline guide evaluates Genital Herpes (Infectious Disease)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Genital Herpes (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Genital Herpes (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Genital Herpes (Infectious Disease) pipeline depth and focus of
  Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction
2. Report Coverage
3. Genital Herpes – Overview
4. Genital Herpes – Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Genital Herpes – Therapeutics Assessment
11. Assessment by Target
12. Assessment by Mechanism of Action
13. Assessment by Route of Administration
14. Assessment by Molecule Type
15. Genital Herpes – Companies Involved in Therapeutics Development

Companies Mentioned

• Abivax S.A.
• Admedus Ltd.
• AiCuris GmbH & Co KG
• Auritec Pharmaceuticals Inc.
• Biomere LLC
• BlueWillow Biologics Inc.
• Immune Design Corp.
• ISR Immune System Regulation Holding AB
• NanoViricides Inc.
• Profectus BioSciences Inc.
• Redbiotec AG
• Sanofi Pasteur S.A.
• Stabilitech Biopharma Ltd.
• Starpharma Holdings Ltd.
• Vaccibody AS
• Vaxart Inc.
• Vir Biotechnology Inc.

Featured News & Press Releases

• May 04, 2017: Admedus Releases Results of HSV-2 Phase IIa Study
• Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine
• Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject
  Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the
  Treatment of recurrent Labial Herpes
• Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II
  Interim Data
• Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging
• Feb 03, 2016: Model helps decide drug dose for clinical testing
• Sep 22, 2015: NanoBio’s Genital Herpes Vaccine Demonstrates Efficacy
  in Guinea Pigs as Both a Prophylactic and a Therapeutic Vaccine
• Aug 17, 2015: Vaxart to Present at the 6th Euro Global Summit and Expo
  on Vaccines and Vaccination in Birmingham, UK on August 18, 2015
• Apr 10, 2015: Admedus has high hopes for Herpes vaccine as dosing
  commences
• Oct 08, 2014: NanoBio To Present Data Demonstrating The Potential For
  Its Intranasal Vaccine To Protect Against Genital Herpes Infection
• Oct 02, 2014: Admedus Announces Further Data From Herpes Simplex
  Vaccine Trial
• Feb 03, 2014: Admedus Herpes Interim Phase I Results
• Oct 17, 2013: Allied Herpes Phase I Trial Progress Update
• Jun 19, 2013: Allied Healthcare Receives Ethical Approval To Commence
  Phase I Clinical Trial Of HSV-2 Vaccine
• Jan 29, 2013: AiCuris Surpasses 50% Enrollment Milestone In Phase II
  Trial For Herpes Drug Pritelivir

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9bffdl/genital_herpes?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs, Sexual
and Reproductive Health Drugs